NHS launches initial phase of new SMA newborn screening in England
Nationwide expansion could prevent early deaths and help dozens of infants
Written by |
- England launched a new NHS newborn screening initiative to test babies for SMA, starting regionally in the West Midlands.
- SMA is a rare genetic condition causing progressive muscle weakness due to the breakdown of motor neurons controlling movement.
- Early detection through newborn screening allows for prompt treatment initiation, preventing permanent nerve damage and improving developmental outcomes.
Babies born in maternity wards across the West Midlands, in England, are now being tested for spinal muscular atrophy (SMA) as part of a new National Health Service (NHS) initiative launched on Oct. 1. The regional rollout marks the first phase of a broader effort to expand newborn screening for the rare genetic disorder across England.
The screening program began at the Birmingham newborn blood spot screening laboratory. According to the UK National Screening Committee (UK NSC), testing will expand in stages to six additional regional laboratories currently participating in newborn screening for severe combined immunodeficiency, a group of rare inherited conditions that severely weaken the immune system.
Health authorities then aim to bring England’s remaining six regional laboratories into the program, making SMA screening available to every newborn in the country.
Why early SMA diagnosis matters
SMA is a rare genetic condition that affects about 1 in every 10,000 babies globally. The condition causes motor neurons — the nerve cells in the brain and spinal cord that control muscle movement — to break down, leading to progressive muscle weakness. Early detection is key to starting treatment before permanent nerve damage occurs, which can substantially improve a child’s physical development and overall outcomes.
The goal of screening is to diagnose SMA before physical symptoms appear, allowing affected babies to receive swift clinical evaluation and treatment. Evidence cited by the UK NSC suggests that nationwide screening across England could prevent approximately three early deaths and two cases requiring permanent breathing support (mechanical ventilation) each year. It could also enable about 30 babies to achieve motor milestones beyond sitting, and allow nearly 37 children to lead largely normal lives.
SMA is now included alongside other serious conditions assessed through England’s routine heel-prick blood spot test, given shortly after birth.
The rollout is structured as an in-service evaluation. Rather than establishing SMA screening as a permanent national program right away, health officials are integrating it into NHS services to allow researchers to collect real-world data on its performance in everyday practice.
The UK NSC recommended this approach to determine whether adding SMA to the standard newborn blood spot program is feasible and effective over the long term. The resulting data will help the UK NSC make a final recommendation about whether routine SMA screening should be sustained nationwide.
As the rollout progresses, NHS England is updating guidance for healthcare professionals and parents, while delivering training ahead of screening launches in each laboratory region. Updated resources are also being prepared for parents whose babies screen positive for SMA.
Leave a comment
Fill in the required fields to post. Your email address will not be published.